Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

In this webinar, expert panelists discuss the key challenges in complex mAb purification and offer practical solutions to optimize downstream processing systems for even the most complex mAb formats.< ...

Tiziana Life Sciences Ltd., which is developing the intranasal fully human anti-CD3 monoclonal antibody foralumab for neurological indications, has reported results from studies using a nasal anti-CD3 ...

The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody ...

Tiziana Life Sciences announces positive results from studies using nasal anti-CD3 mAb in traumatic spinal cord injury: New York Saturday, January 25, 2025, 13:00 Hrs [IST] Tizian ...

The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

ArriVent BioPharma in Newtown Square is working on a deal potentially worth more than $1 billion to acquire the rights for an ...

Anti-IL-4Rα monoclonal antibodies are among the best-selling biologics in this field. MG-K10 is an innovative long-acting anti-IL-4Rα humanizedmonoclonal antibody that simultaneously blocks the ...

Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

Since the pandemic, drug trials that purposely make people vomit, shiver and ache have become a research area of growing ...